All posts by: Michael Zand

About Michael Zand

Immunotherapy in CRC Depends on Identifying Predictive Biomarkers – Targeted Oncology

Continue reading

2018-02-20 NEWS

Targeted Oncology

Immunotherapy in CRC Depends on Identifying Predictive Biomarkers
Targeted Oncology
“There are studies in the first line as well as the adjuvant setting, but we do not have data on those studies. We are starting to see broader testing of solid tumor types in mismatch repair by immunohistochemistry and polymerase chain reaction. We’re

Continue reading

2018-02-20 NEWS

STAT

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval
STAT
ood morning, everyone, and welcome to another working week. Those of you on our side of the pond had, of course, an extended respite thanks to a federal holiday, and we hope your time was relaxing and invigorating, because that oh-so-familiar routine
US FDA Approves AstraZeneca’s Immunotherapy for Lung CancerJournal of Clinical Pathways
AstraZeneca PLC (NYSE:AZN) won crucial approval from US regulators for use in lung cancerBenchmark Monitor

all 5 news articles »

Continue reading

2018-02-20 NEWS

Xconomy

With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy
Xconomy
At a time when uncertainty again swirls around the development of Alzheimer’s disease drugs, research continues in new ways. Through an alliance this morning, Voyager Therapeutics will team with AbbVie to try to use gene therapy tools to help attack
AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight …Endpoints News
AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for …Markets Insider
AbbVie doubles down on tau with Voyager Alzheimer’s dealFierceBiotech
Seeking Alpha
all 6 news articles »
Continue reading

2018-02-20 NEWS

Genetic Literacy Project

CRISPR as a ‘medical sleuth’: Gene-editing tool could detect Zika, Ebola and cancer
Genetic Literacy Project
Some of the world’s leading CRISPR labs have, independently, tweaked CRISPR — adding bursts of light here and rings of DNA there — in ways that could make it even more of a research powerhouse and, possibly, a valuable medical sleuth, able to detect